A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Condition: Chickenpox Interventions: Biological: Investigational varicella vaccine low potency; Biological: Investigational varicella vaccine medium potency; Biological: Investigational varicella vaccine high potency; Biological: Marketed varicella vaccine Lot 1; Biological: Marketed varicella vaccine Lot 2; Biological: Measles, mumps, and rubella vaccine; Biological: Hepatitis A vaccine; Biological: 13-valent pneumococcal conjugate vaccine Sponsors: GlaxoSmithKline; IQVIA, USA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chickenpox | Children | Measles | Measles Vaccine | Meningitis Vaccine | Mumps | Mumps Vaccine | Pneomococcal Vaccine | Research | Study | Vaccines